News | Magnetic Resonance Imaging (MRI) | February 14, 2019

Circle Cardiovascular Imaging and Galgo Medical Enter Distribution and Joint Development Agreement

Agreement will expand use of cardiac MRI to electrophysiology procedures through Circle’s cvi42 cardiovascular imaging platform and Galgo’s ADAS 3D EP planning software

Circle Cardiovascular Imaging and Galgo Medical Enter Distribution and Joint Development Agreement

February 14, 2019 – Circle Cardiovascular Imaging and Galgo Medical recently announced an agreement for distribution and joint development with respect to magnetic resonance imaging (MRI) scanner application products and workflows, with corresponding post-processing capabilities. The focus will be to improve cardiac MRI workflows and diagnostic tools to expand accessibility and use of the modality to electrophysiology procedures such as atrial fibrillation and ventricular tachycardia ablations.

The announcement was made at the Society for Cardiovascular Magnetic Resonance (SCMR) 2019 meeting, Feb. 6-9 in Bellevue, Wash.

Circle’s imaging platform, cvi42 is a cardiovascular imaging reading and reporting solution for cardiac MR, cardiac computed tomography (CT) and cardiac interventional planning. cvi42 provides physicians the tools to accurately quantify and diagnose complex cardiovascular diseases while improving patient outcomes and the effective utilization of healthcare resources. Currently at version 5.10, cvi42 utilizes machine learning and big data, with the machine results demonstrating capabilities within the same range as expert human readers.

Galgo Medical SL is a Barcelona-based company that emerged from the Department of Information Technologies (DTIC) at the Universitat Pompeu Fabra (Barcelona, Spain). Its ADAS 3D family of products is intended for the identification of arrhythmia substrate and the planning of ablation procedures using cardiac MRI and CT.                     

For more information: www.circlecvi.com, www.adas3d.com


Related Content

News | ACC

March 28, 2026-- At ACC.26, Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial examining the ...

Home April 02, 2026
Home
News | ACC

March 30, 2026 — Helen H. Hobbs, M.D., professor in the Eugene McDermott Center for Human Growth and Development and of ...

Home April 01, 2026
Home
News | ACC

March 30, 2026 — At ACC.26 in New Orleans, Esperion presented two post-hoc analyses from CLEAR Outcomes focused on risk ...

Home April 01, 2026
Home
News | ACC

March 30, 2026 — Partho Sengupta, MD, DM, FACC, FASE, was honored as a 2026 Distinguished Scientist (Translational ...

Home March 31, 2026
Home
News | ACC

March 29, 2026 — Medical AI, a company specializing in artificial intelligence-enabled electrocardiogram (ECG) solutions ...

Home March 31, 2026
Home
News | ACC

March 28, 2026 — Randomized controlled trial (RCT) data presented at the American College of Cardiology (ACC) 2026 and ...

Home March 30, 2026
Home
News | ACC

March 25, 2026 — At the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26) in New ...

Home March 27, 2026
Home
News | ACC

March 18, 2026 — UltraSight will present six clinical studies validating the performance of its UltraSight Echosystem at ...

Home March 27, 2026
Home
News | ACC

March 25, 2026 — At ACC.26, GE HealthCare will showcase some of its latest solutions that support clinicians across the ...

Home March 26, 2026
Home
News | ACC

March 24, 2026 — Physicians and investigators from the Smidt Heart Institute at Cedars-Sinai will present research and ...

Home March 26, 2026
Home
Subscribe Now